0000000000064454

AUTHOR

Maria Catena Macaluso

showing 4 related works from this author

Regulatory cytokine gene polymorphisms and risk of colorectal carcinoma.

2006

It is well established that cancer arises in chronically inflamed tissue, and this is particularly notable in the gastrointestinal tract. Classic examples include Helicobacter pylori-associated gastric cancer, hepatocellular carcinoma, and inflammatory bowel disease-associated colorectal cancer. Growing evidence suggests that these associations might be not casual findings. Focusing on individual cytokines has generated evidence that anti-inflammatory cytokine interleukin (IL)-10 and transforming growth factor-beta1 (TGF-beta1) may have a complex role in gastrointestinal carcinogenesis. As an example, IL-10-deficient mice develop severe atrophic gastritis and a chronic enterocolitis, develo…

gene polymorphismsMaleRiskProlineColorectal cancerAtrophic gastritisil-10colorectal cancerMouse model of colorectal and intestinal cancerBiologymedicine.disease_causePolymorphism Single NucleotideGeneral Biochemistry Genetics and Molecular BiologyMetastasisTransforming Growth Factor beta1colorectal cancercytokine genepolymorphismsHistory and Philosophy of ScienceGene FrequencyLeucineGenotypemedicineHumansGenetic Predisposition to DiseaseAllelesGeneral Neurosciencetgf-β1CarcinomaCancermedicine.diseaseInterleukin-10Amino Acid SubstitutionItalyTumor progressionCase-Control StudiesImmunologycolorectal cancer; gene polymorphisms; il-10; tgf-β1FemaleCarcinogenesisColorectal NeoplasmsAnnals of the New York Academy of Sciences
researchProduct

Cytokine Gene Polymorphisms and Breast Cancer Susceptibility

2006

Human breast cancer (BC) is characterized by a considerable clinical heterogeneity. Steroid hormone receptor expression and growth factor receptor expression have been considered suitable diagnostic and prognostic markers, whereas mutations of oncosuppressor and gatekeeper genes have been found associated with an increased risk for this malignancy. To evaluate the role that polymorphisms of genes involved in the regulation of inflammatory response might play in BC susceptibility, we investigated associations between cytokine functionally relevant polymorphisms in 84 BC patients compared to 110 age- and sex-matched controls. TNF-alpha (-308G/A), TGF-beta1 (+869C/T), IL-10 (-1117G/A; -854C/T;…

GeneticsGeneral NeuroscienceHaplotypeCancerBreast NeoplasmsSingle-nucleotide polymorphismBiologymedicine.diseasePolymorphism Single NucleotideGeneral Biochemistry Genetics and Molecular BiologyBreast cancerHistory and Philosophy of ScienceGenotypemedicineCytokinesHumansbreast cancercytokine genepolymorphismsFemaleGenetic Predisposition to DiseaseRestriction fragment length polymorphismbreast cancer; cytokine polymorphisms; susceptibilityGeneAllele frequencyAnnals of the New York Academy of Sciences
researchProduct

Analysis of interleukin 10 (IL-10) -1082G/A single nucleotide polymorphism (SNP) genotypes in breast cancer (BC) patients (pts) and in >95 years o…

2005

9656 Background:the anti-inflammatory IL-10 -1082 (G/A) SNP might be associated with different risk for breast tumor development. The -1082GG homozygous genotype is associated with an higher IL-10 ...

GeneticsOncologyCancer Researchmedicine.medical_specialtybusiness.industryHomozygous genotypeCancer-FreeSingle-nucleotide polymorphismmedicine.diseaseBreast tumorInterleukin 10Breast cancerOncologyInternal medicineGenotypemedicineSNPbusinessJournal of Clinical Oncology
researchProduct

“Weekly docetaxel and gemcitabine as first line treatment for metastatic breast cancer: results of a multicenter phase II study”

2004

<i>Objectives:</i> We conducted a multicenter phase II study to evaluate the clinical efficacy, toxicity, and dose intensity of a new weekly schedule of docetaxel and gemcitabine as first-line treatment of metastatic breast cancer patients. <i>Methods:</i> We enrolled 58 patients, 52% of whom had received a previous anthracycline-containing chemotherapy. The treatment schedule was: docetaxel 35 mg/m<sup>2</sup> and gemcitabine 800 mg/m<sup>2</sup> i.v. on days 1, 8, 15 every 28 days. <i>Results:</i> All patients were assessable for toxicity and 56 for efficacy. Overall response rate was 64.3% with 16.1% of complete responses and 48…

OncologyAdultCancer Researchmedicine.medical_specialtyMaximum Tolerated Dosemedicine.drug_classPhases of clinical researchBreast NeoplasmsDocetaxelAntimetaboliteDeoxycytidineMetastasisBreast cancerInternal medicineAntineoplastic Combined Chemotherapy ProtocolsMedicineHumansAgedNeoplasm Stagingbusiness.industryCarcinoma Ductal BreastGeneral MedicineMiddle Agedmedicine.diseaseMetastatic breast cancerGemcitabineGemcitabineSurgerySurvival RateCarcinoma LobularTreatment OutcomeOncologyDocetaxelCarcinoma MedullaryToxicityFemaleTaxoidsbusinessmedicine.drug
researchProduct